Figure 3. MiRNA-150 plays an oncogenic role in GC in vitro. (A) MiRNA-150 enhanced cell proliferation. Cell proliferation was determined in BGC-823 cells using a CCK8 assay. (B) The expression level of miRNA-150 in BGC-823 cells decreased successfully after transfection with miRNA-150 inhibitors. (C) MiRNA-150 boosted cell migration. The migratory ability of BGC-823 cells was assessed using a Transwell assay. Five fields in each well were randomly chosen to measure migration. The experiment was repeated three times. (D) MiRNA-150 inhibition impaired the migration ability of BGC-823 cells. Five fields in each wound were randomly chosen to measure migration. The experiment was repeated three times. (E) Overall survival (OS) and progression-free survival (PFS) in groups with high and low expression of miRNA-150 were analyzed using a Kaplan–Meier survival analysis of the ATGC data of patients with stage III and IV GC. *p<0.05.